Pharmacokinetic Evaluation of NEX-22A in Patients with Type 2 Diabetes: A Phase 1 Clinical Trial

The primary objective of this Phase 1 study is to assess the **pharmacokinetics** of NEX-22A in subjects with **Type 2 diabetes**. Understanding the pharmacokinetics is clinically relevant as it provides critical information on how the drug is absorbed, distributed, metabolized, and excreted in this specific patient population. This data is essential for determining appropriate dosing regimens and ensuring the safety and efficacy of NEX-22A in managing Type 2 diabetes.

The clinical trial involves participants diagnosed with **Type 2 diabetes**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been specified. The trial population was selected to include a broad representation of individuals with the condition, without specific emphasis on any particular subgroup.

The clinical trial is designed to evaluate the **pharmacokinetics** of NEX-22A in subjects diagnosed with **Type 2 diabetes**. This is a Phase 1 study, which will be conducted as a randomized, double-blind, and controlled trial. The estimated recruitment start date is March 15, 2024, with an anticipated end date of May 30, 2024, making the overall trial duration approximately two and a half months. Participants will be involved in a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This visit is crucial for ensuring that only suitable candidates are enrolled in the study.

Following the inclusion visit, participants will undergo a series of follow-up visits. These visits are scheduled to monitor the participants' response to the investigational product and to collect necessary data for the study's objectives. The sequence and frequency of these visits are determined by the study protocol to ensure comprehensive data collection while maintaining participant safety. The end-of-study visit marks the conclusion of the participant's involvement in the trial, where final assessments are conducted, and any remaining study-related procedures are completed.

The expected length of participant involvement is aligned with the trial's overall duration, approximately two and a half months, unless early termination is warranted. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted under strict adherence to ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on March 15, 2024, with an estimated end date of May 30, 2024. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The trial's primary focus is to evaluate the efficacy of the intervention under investigation, adhering to the rigorous standards expected in a Phase 3 clinical trial. The study will employ validated methodologies to ensure the reliability and validity of the efficacy outcomes, although specific tools or instruments are not mentioned. The trial's design and execution will align with the regulatory and scientific standards for clinical research, ensuring that the findings contribute valuable insights into the treatment's efficacy.